BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Promoting RNF208 expression in metastatic breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Increasing the expression of RNF208, an estrogen-inducible E3 ligase, could treat metastatic triple-negative breast cancer (TNBC). RNA levels of RNF208 were lower in tumor tissue from patients with TNBC...
BioCentury | Aug 8, 2019
Distillery Therapeutics

RNF2 inhibition to treat prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting the RNF2 subunit of PRC1 could treat double-negative prostate cancer (DNPC), a subtype of metastatic prostate cancer characterized by a non-responsive androgen receptor pathway and lacking neuroendocrine traits....
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Aug 9, 2018
Translation in Brief

Identifying the ubiquitinators

A team at University of Dundee and Newcastle University has developed a mass spectrometry-based screening platform to identify ubiquitin ligases and compounds that modulate them. The approach uses the uptake of ubiquitin by enzymes rather...
BioCentury | Aug 1, 2018
Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays; high throughput screening A high throughput, mass spectrometry-based screening assay could identify E3 ligase inhibitors and interactive pairs of E2/E3 ubiquitination enzymes as potential drug targets. For the latter, the method involves...
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

New Therapeutic Targets and Biomarkers: May 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | May 16, 2018
Distillery Therapeutics


INDICATION: Cystic fibrosis (CF) Cell culture studies identified a phenylbenzimidamide-based RNF5 inhibitor that could help treat CF in patients harboring the ΔF508 loss-of-function mutation in CFTR. In silico screening of a small molecule library for...
BioCentury | May 11, 2018
Preclinical News

Inhibiting the ubiquitin ligase RNF5 to treat CF

In a paper published in Cell Chemical Biology , Italian researchers identified a pharmacological inhibitor of ring finger protein 5 (RNF5) that prevented the premature degradation of mutant F508del cystic fibrosis transmembrane conductance regulator (CFTR) protein,...
BioCentury | Apr 25, 2018
Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in Nature...
Items per page:
1 - 10 of 25